# Save Medical Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/save-medical

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: https://savemedical.jp
- Total disclosed funding: $5.9M
- Latest round: Series C (Jul 14, 2021)
- Investors on record: 6

## About

Save Medical Corporation is a healthcare technology firm that specializes in consulting for Software as Medical Devices (SaMD) and Digital Therapeutics (DTx), enabling clients to navigate the complexities of product commercialization and regulatory compliance.Founded in 2018 in Tokyo, Japan, Save Medical Corporation focuses on providing consulting services tailored for SaMD and DTx sectors. The company has successfully completed 4 deals, with its most recent funding round being a SERIES C raising JPY 50 million on July 22, 2024, from investor TIS. Shotaro Asano serves as both the Founder and CEO, leveraging his expertise to guide the company's strategic initiatives.Save Medical specializes in the intersection of healthcare and technology, offering solutions that integrate innovative ideas and advanced technologies to tackle various healthcare challenges. The company's primary service is consulting for companies developing Software as Medical Devices (SaMD), focusing on business strategy, regulatory affairs, and Quality Management System (QMS) development. Additionally, Save Medical leverages its expertise in Digital Therapeutics (DTx) to assist clients in commercializing digital health products, providing end-to-end support from concept to market launch. Their client base primarily includes healthcare providers and technology firms seeking to enhance patient outcomes through digital solutions. Save Medical operates in diverse geographical markets, targeting regions such as North America, Europe, and parts of Asia where digital health solutions are increasingly in demand.Save Medical generates revenue through consulting services that are tailored for companies in the SaMD and DTx sectors. The business model primarily involves B2B transactions, where clients engage Save Medical for specialized consulting contracts that may span several months, depending on project complexity. The revenue structure includes fixed fees for defined consulting services as well as potential performance-based incentives tied to successful product launch outcomes. Save Medical’s offerings, which include strategic guidance and technical support, are positioned to meet the needs of a growing market in digital health, ensuring that their clients can effectively navigate regulatory landscapes and achieve successful product commercialization. Specific pricing plans for their consulting services are determined based on the scope and duration of engagement, reflecting the bespoke nature of the solutions they provide.In July 2024, Save Medical Corporation raised JPY 50 million in SERIES C funding from new investor TIS. This funding will be utilized to provide total support for Digital Therapeutics (DTx) and Software as Medical Devices (SaMD) processes. The company plans to expand its footprint into new geographic regions, particularly targeting additional markets in North America and Europe by mid-2025. Save Medical is also working on launching new product offerings aimed at enhancing its consulting services tailored to the evolving needs of its client base.

## Funding rounds

- Series C, Jul 14, 2021, $2.7M — Bonds Investment Group, Spiral Capital
- Series B, Jan 15, 2020, $3.2M — Electric Power Development, Mitsubishi UFJ Capital, MACNICA, Inc., FFG Venture Business Partners

## Investors

- Electric Power Development — Series B
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- MACNICA, Inc. — Series B
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series B
- Bonds Investment Group (https://capitalatlas.ai/funds/bonds-investment-group) — Series C
- Spiral Capital (https://capitalatlas.ai/funds/spiral-capital) — Series C